Finance

Lists
FLNA:BMV
Filana Therapeutics Inc
15,92 MX$
0,00%
(0,00) 1D
5 ოქტ, 12:05:31 GMT-6  ·   MXN
All symbols
SymbolPriceChange% Change
Generating top insights for FLNA...
Mkt. cap
34,02 მლნ.
Avg. vol.
0,00
Volume
0,00
52-wk high
56,00 MX$
52-wk low
15,92 MX$
No. of employees
19
Mkt. cap
34,02 მლნ.
Avg. vol.
0,00
Volume
0,00
52-wk high
56,00 MX$
52-wk low
15,92 MX$
No. of employees
19
News stories
From web sources and news partners
Profile
Filana Therapeutics, Inc. is an American pharmaceutical company based in Austin, Texas. Currently led by President and CEO Richard Barry, Filana is working on developing simufilam to treat tuberous sclerosis complex–related epilepsy. The company previously was developing simufilam as an oral-tablet drug candidate for the treatment of Alzheimer's disease. Development of simufilam was discontinued in November 2024 after it failed to show clinical benefit in phase III clinical trials. In June 2024, the United States Department of Justice charged an advisor to Cassava Hoau-Yan Wang, with fraud over research results related to the experimental drug. Less than a month later, the president, chief executive officer and chairman of the board, Remi Barbier, resigned along with Lindsay Burns, his wife, who was the company's senior vice president and Wang's co-author. The U.S. Securities and Exchange Commission filed fraud charges in September 2024 against Barbier, Burns and Wang. The parties did not admit wrongdoing, but agreed to pay fines of the company $40 million, Barbier $175,000, Burns $85,000, and Wang $50,000. Wikipedia
About Filana Therapeutics Inc
CEO-
Employees19
Founded1998
Headquartersოსტინი, ტეხასი, ამერიკის შეერთებული შტატები
SectorPharmaceutical industry
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
სექ. 2025
დეკ. 2025
მარ. 2026
ივნ. 2026
Revenue
-
-
-
-
Cost of goods sold
3,96 მლნ.
3,85 მლნ.
4,54 მლნ.
3,30 მლნ.
Cost of revenue
3,96 მლნ.
3,85 მლნ.
4,54 მლნ.
3,30 მლნ.
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
7,90 მლნ.
5,70 მლნ.
6,62 მლნ.
6,09 მლნ.
Operating expense
7,90 მლნ.
5,70 მლნ.
6,62 მლნ.
6,09 მლნ.
Total operating expenses
11,86 მლნ.
9,55 მლნ.
11,17 მლნ.
9,39 მლნ.
Operating income
-11,86 მლნ.
-9,55 მლნ.
-11,17 მლნ.
-9,39 მლნ.
Other non operating income
-114,00 ათ.
39,00 ათ.
48,00 ათ.
43,00 ათ.
EBT including unusual items
-10,81 მლნ.
-12,54 მლნ.
-10,33 მლნ.
-8,60 მლნ.
EBT excluding unusual items
-10,81 მლნ.
-8,54 მლნ.
-10,33 მლნ.
-8,60 მლნ.
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-10,81 მლნ.
-12,54 მლნ.
-10,33 მლნ.
-8,60 მლნ.
Net profit margin
-
-
-
-
Earnings per share
-
-
-
-
Interest and investment income
1,17 მლნ.
974,00 ათ.
789,00 ათ.
747,00 ათ.
Interest expense
-
-
-
-
Net interest expenses
1,17 მლნ.
974,00 ათ.
789,00 ათ.
747,00 ათ.
Depreciation and amortization charges
-
-
-
-
EBITDA
-11,73 მლნ.
-9,18 მლნ.
-10,92 მლნ.
-9,15 მლნ.
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
Google აპები